(13S,16S)-1-cyclopropyl-7-fluoro-16-[2-fluoro-4-((5R)-2-oxo-5-tetrazol-1-ylmethyl-oxazolidin-3-yl)-phenoxymethyl]-16-hydroxy-4-oxo-1,4,13,15,16,17-hexahydro-12H-11-oxa-1,14-diaza-cyclopenta[a]phenanthrene-3-carboxylic acid benzyl ester | 926279-50-7

• 分子结构分类: 有机化合物
• 英文名称: (13S,16S)-1-cyclopropyl-7-fluoro-16-[2-fluoro-4-((5R)-2-oxo-5-tetrazol-1-ylmethyl-oxazolidin-3-yl)-phenoxymethyl]-16-hydroxy-4-oxo-1,4,13,15,16,17-hexahydro-12H-11-oxa-1,14-diaza-cyclopenta[a]phenanthrene-3-carboxylic acid benzyl ester
• 英文别名: benzyl (13S,15S)-3-cyclopropyl-9-fluoro-13-[[2-fluoro-4-[(5R)-2-oxo-5-(tetrazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenoxy]methyl]-13-hydroxy-6-oxo-17-oxa-3,11-diazatetracyclo[8.7.0.02,7.011,15]heptadeca-1,4,7,9-tetraene-5-carboxylate
• CAS: 926279-50-7
• 化学式: C₃₇H₃₃F₂N₇O₈
• 分子量: 741.708
• InChiKey: CQFXGYSESZQDHU-UNWNKWTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  54
• 可旋转键数：
  11
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  162
• 氢给体数：
  1
• 氢受体数：
  15

文献信息

• Novel Antibacterial Compounds
  申请人：Hubschwerlen Christian

  公开号：US20100222302A1

  公开（公告）日：2010-09-02

  The invention relates to novel chimeric antibiotics of formula I wherein R 1 is CH 2 NHCOR 5 , heteroarylmethyl, heteroaryloxymethyl or heteroarylaminomethyl; R 2 is H, OH, OSO 3 H, OPO 3 H 2 , OCH 2 OPO 3 H 2 , OCOCH 2 CH 2 COOH, OCOR 6 ; R 3 is H or halogen; R 4 is (C 1 -C 3 )alkyl, (C 1 -C 3 )haloalkyl or cycloalkyl; R 5 is alkyl or haloalkyl; and R 6 is the residue of a naturally occurring amino acid or of dimethylaminoglycine. These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).

  该发明涉及一种新型嵌合抗生素，其化学式为I，其中R1为CH2NHCOR5，杂环烷基甲基，杂环氧甲基或杂环氨基甲基；R2为H，OH，OSO3H，OPO3H2，OCH2OPO3H2，OCOCH2CH2COOH，OCOR6；R3为H或卤素；R4为（C1-C3）烷基，（C1-C3）卤代烷基或环烷基；R5为烷基或卤代烷基；R6为天然氨基酸残基或二甲氨基甘氨酸残基。这些嵌合化合物在制造治疗感染（例如细菌感染）的药物中非常有用。
• Oxazolidinone-quinolone hybrids as antibacterial compounds
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2256120A1

  公开（公告）日：2010-12-01

  The invention relates to novel chimeric antibiotics of formula I wherein R1 is heteroarylmethyl, heteroaryloxymethyl or heteroarylaminomethyl; R2 is H, OH, OSO3H, OPO3H2, OCH2OPO3H2, OCOCH2CH2COOH, OCOR6; R3 is H or halogen; R4 is (C1-C3)alkyl, (C1-C3)haloalkyl or cycloalkyl; R6 is the residue of a naturally occurring amino acid or of dimethylaminoglycine. These chimeric compounds are useful in the manufacture of medicaments for the treatment of infections (e.g. bacterial infections).

  本发明涉及式 I 的新型嵌合抗生素 其中 R1 是杂芳基甲基、杂芳氧基甲基或杂芳基氨基甲基； R2 是 H、OH、OSO3H、OPO3H2、OCH2OPO3H2、OCOCH2CH2COOH、OCOR6； R3 是 H 或卤素 R4 是 (C1-C3)烷基、(C1-C3)卤代烷基或环烷基； R6 是天然氨基酸或二甲氨基甘氨酸的残基。 这些嵌合化合物可用于制造治疗感染（如细菌感染）的药物。